News & Media

Press Release

BillionToOne's Northstar Select® Demonstrates Superior Sensitivity in Prospective Head-to-Head Validation Study Publication

August 26, 2025

Press Release

BillionToOne's Northstar Select® Demonstrates Superior Sensitivity in Prospective Head-to-Head Validation Study Publication

August 26, 2025

Media Coverage

BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test

April 26, 2025

Media Coverage

BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test

April 26, 2025

Media Coverage

BillionToOne’s Northstar Response® Validated in New Peer-Reviewed Study, Building on Previous Clinical Research

March 3, 2025

Press Release

BillionToOne’s Northstar Response® Validated in New Peer-Reviewed Study, Building on Previous Clinical Research

March 3, 2025

General Information

The Power of One: Using Single Molecule Sensitivity Diagnostics to Fight Cancer

February 4, 2025

General Information

The Power of One: Using Single Molecule Sensitivity Diagnostics to Fight Cancer

February 4, 2025

Media Coverage

ASCO24: BillionToOne unveils results from tumour profiling test comparison

June 6, 2024

Media Coverage

ASCO24: BillionToOne unveils results from tumour profiling test comparison

June 6, 2024

Act with certainty. Adapt with precision.

Get in Touch

BillionToOne's Northstar Select® Demonstrates Superior Sensitivity in Prospective Head-to-Head Validation Study Publication

BillionToOne's Northstar Select® Demonstrates Superior Sensitivity in Prospective Head-to-Head Validation Study Publication

BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test

BillionToOne Pushing Forward in Cancer Diagnostics With First Data on Response Monitoring Test

Medicare Covering BillionToOne Northstar Select Cancer Liquid Biopsy Test

Medicare Covering BillionToOne Northstar Select Cancer Liquid Biopsy Test

BillionToOne Announces Medicare Coverage for Northstar Select®

BillionToOne Announces Medicare Coverage for Northstar Select®

Methylation Monitoring Predicts Pan-Cancer Outcomes

Methylation Monitoring Predicts Pan-Cancer Outcomes

BillionToOne’s Northstar Response® Validated in New Peer-Reviewed Study, Building on Previous Clinical Research

BillionToOne’s Northstar Response® Validated in New Peer-Reviewed Study, Building on Previous Clinical Research

The Power of One: Using Single Molecule Sensitivity Diagnostics to Fight Cancer

The Power of One: Using Single Molecule Sensitivity Diagnostics to Fight Cancer

ASCO24: BillionToOne unveils results from tumour profiling test comparison

ASCO24: BillionToOne unveils results from tumour profiling test comparison

Our Newsletter

Act with certainty. Adapt with precision.